Ultimate Assessment Program 2027/28/29 || 1:1 Mentorship Batch Admissions Open

Social Justice › Health

Single-use medical devices: ban on reuse and who decides what is safe

·

Why in the News

Indian hospitals have moved from reusing costly single-use medical devices without consistent protocols to a complete ban on such reuse. The Directorate-General of Health Services (DGHS) issued the ban to protect patients. Yet the single-use label is usually set by the manufacturer, not by an independent regulator that has tested whether reuse is safe.

What is the ban on reusing single-use devices?

  1. Single-use device: A device whose label says it must be discarded after one patient. Eg. A costly surgical stapler used in liver transplants.
  2. Why reuse happened: Many such devices are so costly that Indian hospitals reused them until unsafe, sharing the cost across several patients.
  3. The directive: The DGHS directive of October 16 bans reuse of devices labelled single use in every public and private healthcare facility.
  4. Grounds cited: The directive cites the risk of infection and possible breaches of existing laws. It also cites patients and government schemes charged full price for reused devices.
  5. The takeaway: The ban protects patients from unsafe reuse and overbilling, but it also ends the cost sharing that made some treatment affordable.

Who decides that a device is single-use?

  1. Manufacturer’s label: The single-use label is usually decided by the manufacturer, not by a regulator that has checked reuse (two 2018 *Heart Asia* editorials by Thomas Crawford, Kim Eagle and colleagues).
  2. Commercial incentive: Testing a device for reuse is expensive, and every discarded device is a fresh sale, so the label saves the maker money.
  3. Genuine limits: Many devices have narrow tubes, fine hinges and delicate coatings that are hard to clean and inspect, so some limits on use are justified.

Why is India’s record on reuse a concern?

  1. No protocols: Hospitals have reprocessed devices for years without consistent protocols, tracking or any systematic record of patient outcomes.
  2. Maharashtra probe: In 2017, Maharashtra’s Food and Drug Administration reportedly investigated eight private hospitals over reuse of catheters, thin tubes inserted into the body.
  3. Scale of reuse: That probe covered 1,306 catheters used on more than 1,000 patients.
  4. Overbilling: Patients were reportedly charged a large part of the maximum retail price for reused balloon catheters.

What does regulated reprocessing require, and how do other countries handle it?

  1. Reprocessing: Cleaning, sterilising and testing a used device so it can be used again. A device can be sterile yet weakened, unreliable or contaminated where cleaning does not reach.
  2. Proof required: A reprocessor must show that cleaning and sterilisation work, the device still performs, and the process meets quality and reporting standards.
  3. United States: The US Food and Drug Administration treats anyone who reprocesses a single-use device as a manufacturer, with the same regulatory duties.
  4. Other jurisdictions: Canada, Japan and the European Union also regulate reprocessing, each with its own rules.

Challenges

  1. Affordability: Surgeons and doctors warn that a blanket ban raises costs for patients and schemes that relied on reuse.
  2. Interested labelling: The firm that profits from each new sale decides whether a device is single-use.
  3. No evidence base: India lacks independent studies on which devices can be safely reprocessed.
  4. Costly devices: Expensive devices are not made at home in enough numbers, so cost pressure pushes hospitals towards unsafe practices.

Way Forward

  1. Three-way sorting: A national programme should sort devices into never reprocess, reprocess under tested and regulated conditions, and insufficient evidence needing research.
  2. Approved facilities: Permit reprocessing only in approved facilities with tested methods, a recorded reuse limit and tracing of each device.
  3. Reporting and audits: Make failure and complication reporting compulsory, with independent audits.
  4. Patient disclosure: Label reprocessed devices, tell patients whether a device is new, and disclose the savings passed on.
  5. Domestic manufacture: Make more costly devices in India and fund independent Indian studies on safety, performance and value for money.

Conclusion

The ban settles the safety question for now but leaves affordability to a label set by sellers rather than by evidence. The test is whether India builds a regulator-led system that decides, device by device, what can be safely reused.

Back2Basics: Directorate-General of Health Services

  1. What it is: An attached office of the Union Ministry of Health and Family Welfare that gives technical advice on medical and public health matters.
  2. Device regulator under it: The Central Drugs Standard Control Organisation (CDSCO), headed by the Drugs Controller General of India, functions under the DGHS.
  3. Legal basis for devices: Medical devices are regulated under the Medical Devices Rules, 2017, framed under the Drugs and Cosmetics Act, 1940.

Matching Previous Year Question

“[2018] Consider the following statements: 1. The Food Safety and Standards Act, 2006 replaced the Prevention of Food Adulteration Act, 1954. 2. The Food Safety and Standard Authority of India (FSSAI) is under the charge of Director General of Health Services in the Union Ministry of Health and Family Welfare. Which of the statements given above is/are correct? (a) 1 only (b) 2 only (c) Both 1 and 2 (d) Neither 1 nor 2 ANSWER: (a)”

Click here to Download X-Factor Notes for FREE. Cover the entire Microthemes with PYQs.

Download free X-Factor Notes
Revised and updated X-Factor Notes for UPSC Mains 2026: nine subject booklets